Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A first-in-human, randomized, double-blind, placebo-controlled Phase 1/2 study of AGT100216 in healthy adult volunteers

Next Previous
Trial Profile

A first-in-human, randomized, double-blind, placebo-controlled Phase 1/2 study of AGT100216 in healthy adult volunteers

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 30 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AGT 100216 (Primary)
  • Indications Charcot-Marie-Tooth disease; Peripheral neuropathies
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 27 May 2025 Status changed from planning to recruiting, according to an Augustine Therapeutics media release.
  • 24 Mar 2025 According to an Augustine Therapeutics media release, company successfully completed its Series A financing round raising a total of EUR 77.7 million (USD 84.8 million). These proceeds will be used to support the clinical development AGT-100216 for the treatment of Charcot-Marie-Tooth (CMT) disease, with Phase I trials.
  • 13 Feb 2025 According to an Augustine Therapeutics media release, AGT100216, a small molecule non-hydroxamic acid HDAC6 enzyme inhibitor, is poised to enter the clinic later this year for Charcot-Marie-Tooth disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top